5-(3-chloro-5-methylphenyl)-N-[(1-methyl-1H-indol-2-yl)methyl]-2-(1-methyl-1H-pyrazol-4-yl)nicotinamide | 1112850-28-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-(3-chloro-5-methylphenyl)-N-[(1-methyl-1H-indol-2-yl)methyl]-2-(1-methyl-1H-pyrazol-4-yl)nicotinamide
• 英文别名: 5-(3-chloro-5-methylphenyl)-N-[(1-methylindol-2-yl)methyl]-2-(1-methylpyrazol-4-yl)pyridine-3-carboxamide
• CAS: 1112850-28-8
• 化学式: C₂₇H₂₄ClN₅O
• 分子量: 469.973
• InChiKey: SDCKPZLUYVZQHK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  34
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  64.7
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Pyridine Carboxamide orexin Receptor Antagonists
  申请人：Bergman Jeffrey M.

  公开号：US20110301140A1

  公开（公告）日：2011-12-08

  The present invention is directed to pyridyl carboxamide compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.

  本发明涉及吡啶基羧酰胺化合物，其是促睡素受体的拮抗剂，可用于治疗或预防神经系统和精神疾病，以及促睡素受体参与的疾病。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗促睡素受体参与的疾病中的使用。
• US8003797B2
  申请人：——

  公开号：US8003797B2

  公开（公告）日：2011-08-23